Your Article Summary
See Latest ArticlesCytokinetics Announces the Initiation of a First-Time-In-Humans, Phase I Clinical Trial of CK-2017357
Cytokinetics, 06/19/09
Cytokinetics, Incorporated announced that the company has initiated a first-time-in-humans, Phase I clinical trial of CK-2017357 in healthy male volunteers. CK-2017357 is a fast skeletal muscle troponin activator and is the lead drug candidate that has emerged from the company’s skeletal sarcomere activator program. CK-2017357 selectively activates the troponin complex and increases its sensitivity to calcium, subsequently leading to an increase in skeletal muscle force.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09